| Name | Title | Contact Details |
|---|
Kloeckner Metals - Americas is a prominent steel and metal distributor based in Roswell, Georgia. As the North American subsidiary of Klöckner & Co SE, it ranks as the fourth-largest metal service center in North America, operating around 50 locations across the U.S., Mexico, Canada, and Puerto Rico. The company serves approximately 8,000 metalworking businesses with a diverse portfolio of over 190,000 products, including carbon steel, stainless steel, and aluminum. The company offers extensive services beyond distribution, such as custom processing, warehousing, logistics solutions, and supply chain management. This comprehensive approach helps customers optimize production schedules and reduce lead times by providing materials close to their operations. Kloeckner Metals supports various industries, including automotive, construction, energy, and infrastructure, ensuring that its customers have access to the products and services they need for their projects.
Nobell Foods is creating cheese and other dairy products from plant-derived dairy proteins for the 99% of people who are unwilling to compromise on taste and price. Worldwide dairy production accounts for 40% of global livestock emissions. In the US, the dairy industry is responsible for 2% of the nation`s greenhouse gas emissions. And a growing chunk of that dairy consumption is coming from cheese. Our team is made up of passionate scientists, explorers, and storytellers on a mission to radically change the way we make food, so it`s better for you, the animals and the planet. We are backed by Bill Gates` climate fund Breakthrough Energy Ventures, Andreessen Horowitz, and Robert Downey Jr.`s footprint coalition.
Mechanics is a Ohio-based community bank that offers services including personal and business banking, trust, mortgages and loans for individuals and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.